USPTO Patents Application 09993647

ElcwilUlllw nwlMlUWlcUMclllclll newel IJ 1

EFSID:

7717842

Application Number:

09993647

International Application Number:

Confirmation Number:

1010

Title of Invention:

omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

First Named Inventor/Applicant Name:

Bernd Riedl

Customer Number:

23599

Filer:

Csaba Henter

Filer Authorized By:

Attorney Docket Number:

BAYER 18A

Receipt Date:

01-JUN-2010

Filing Date:

27-NOV-2001

Time Stamp:

13:15:36

Application Type:

Utility under 35 USC 111(a)

Payment information:

Submitted with Payment

no

File Listing:

Document
Number

Document Description

File Name

FileSize(Bytes)/
Message Digest

Multi
Part /.zip

Pages
(if appl.)

1

NPL Documents

PI 7-

BERGESTEPHENMLYLEDBIGHLE
YANDDONALDCMONKHOUSEP
HARMACEUTICALSALTS.pdf

2779981

24d4aa003e1 a22d855791f541 addbfl 0ad2
6540d

no

19

Warnings:

Information:

2

NPL Documents

P18-Bergstralh-
MicrotubuleStabilizingAgentsT
heirMolecularSignalingConseq
uences.pdf

1440893

no

14

efe0ca68a2221 58b8dddf2ec4492261 cbdd
437a4

Warnings:

Information:

3

NPL Documents

PI 9-

BERTRANDFEETALINHIBITIONO
FPI3KMTORANDMEKSIGNALIN
GPATHWAYS.pdf

438413

no

5

41e44c095ced82a23a8fede6e54fab521342
a713

Warnings:

Information:

4

NPL Documents

P20-BHAGWAT-
AngiogenicRegulatorCDI 3APN.
pdf

1 1 57025

no

9

ab5816af95920ab9a0fa0c960004c969210b
14e0

Warnings:

Information:

5

NPL Documents

P21-BIANCHIETAL-
MulticenterUncontrolledTrial.
pdf

1439972

no

33

81ef8db8730fcd2785cc408f46546a4c47a8
3fe8

Warnings:

Information:

6

NPL Documents

P22-Martin-Blanco-p38MAPK.
pdf

212665

no

9

9b6d919dbea7158136b66ceac569b372bb
C71781

Warnings:

Information:

7

NPL Documents

P23-Foussard-Blanpin-
ComparitivePharmacodynamic
study.pdf

324049

no

12

7673a4217ac16d6b526a4a4745c2b0a443c
d47d8

Warnings:

Information:

8

NPL Documents

P25-BOLLAGETAL-
RAFPathwaylnhibitors.pdf

570524

no

6

1 24e6f8014aca1 cadi 1 e69dc70a8191 aOdb
759e8

Warnings:

Information:

9

NPL Documents

P26-

BoltonetalOncogeneDirectedA
pproachesinCancerChemother
apy.pdf

1322358

no

10

3d861bca2a7bd236e2a3b2f6a645 b585b7b
14221

Warnings:

Information:

10

NPL Documents

P26a-Bono-et-al-Blood-v1 03-
n8-p2929.pdf

481721

no

7

17dde6c8e25ee5d3f11202b97142bd4c0cc
c2d0f

Warnings:

Information:

11

NPL Documents

P24-BOARDETAL-
PlateletDerivedGrowth.pdf

948188

no

10

b4f08ac5c7c822fd84b547b8e36f85803 1 a9
cbOO

Warnings:

Information:

12

NPL Documents

P24a-Bok-Cancer-Res-v61 -
p2533.pdf

896719

no

4

71 d8b1 6e21fe97a365438dc5dceda95a580
daceb

Warnings:

Information:

13

NPL Documents

P27-

BosrasOncogenesinHumanCan
cerAReview.pdf

903184

no

8

93ffba15bb2c81caa83602dc55926b1018b
8b9db

Warnings:

Information:

14

NPL Documents

P28-

BoultonetalHeterocyclicRearra
ngementsPartXAGeneralisedM
onocyclicRearrangement.pdf

524828

no

4

46aec3f3ca8ffbe790b3d6bf065c03af7fca02
4c

Warnings:

Information:

15

NPL Documents

P28a-

BoyerSmallMoleculelnhibitorso
fKDR.pdf

2453975

no

28

41b072c857def1b0cfea15ffe6e34f525f878
b9c

Warnings:

Information:

16

NPL Documents

P29-

BOYDDEREKETALARENEOXIDES
OFQUINOLINE.PDF

374690

no

4

97aad8c9cd3cfbae0671 bb7620541 1406e9
8d43e

Warnings:

Information:

17

NPL Documents

P29a-Braybrooke-et-al-Clin-
Cancer-Res-v6-n12-p4697.pdf

1546108

no

8

d7c3b8fa1e41c694cb43ad44d394285cbd6
af8c5

Warnings:

Information:

18

NPL Documents

P29b-Broll-et-al-Eur-J-Surg-
Oncol-v27-n1-p37-1.pdf

1 706850

no

6

fd938158c516dac7a0096b52a95f67ec8094
ca37

Warnings:

Information:

19

NPL Documents

P30-

BruderetalAdenoviruslnfection
StimulatestheRafMAPKSignalin
gPathway.pdf

752028

no

7

C058fbfdd8530d768880ec4a34659bf9b297
81a1

Warnings:

Information:

20

NPL Documents

P31-

BUNDGAARDHANSDESIGNOFP
RODRUGS.pdf

8338284

09911e889c8cl5a51f2795fcl5e51ec27b92ef
2aec

no

94

Warnings:

Information:

Total Files Size (in bytes)

28612455

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents,
characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 1 1 1

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR
1 .53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1 .54) will be issued in due course and the date shown on this
Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35
U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a
national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for
an international filing date (see PCT Article 1 1 and MPEP 1 81 0), a Notification of the International Application Number
and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning
national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of
the application.